SCHEMBL725121

SCHEMBL725121

CON(C)C(=O)c1cccc(-c2ccccc2)n1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
KAT6A Q92794 2/20 0.44
CNR2 P34972 4/20 0.43
CNR1 P21554 1/20 0.43
HSD17B14 Q9BPX1 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
TRPM8 Q7Z2W7 2/20 0.41
CTSA P10619 1/20 0.41
P2RY12 Q9H244 2/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
ASIC3 Q9UHC3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15849615 0.84 MEN1 (0.50) RAB9AMEN1KMT2AKAT6ACNR2
SCHEMBL8374791 0.84 KDM4E (0.45) RAB9AMEN1KMT2ATRPM8ALDH1A1
SCHEMBL5309392 0.78 OXTR (0.46) RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL3739445 0.78 P2RX7 (0.49) RAB9AMEN1KMT2AADORA3TRPM8
SCHEMBL1260197 0.78 ALDH1A1 (0.52) RAB9AMEN1KMT2AKAT6ACNR2
SCHEMBL770109 0.77 KMO (0.60) RAB9AKMT2AADORA3ALDH1A1SMN1; SMN2
SCHEMBL306066 0.76 ALDH1A1 (0.41) RAB9AMEN1KMT2ATRPM8CTSA
SCHEMBL307224 0.76 GRM4 (0.46) RAB9AMEN1KMT2ATRPM8CTSA
SCHEMBL4088056 0.76 GRM5 (0.43) MEN1KMT2ATRPM8CTSAALDH1A1
SCHEMBL31546875 0.76 CTSA (0.40) MEN1KMT2ATRPM8CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
EP-2608671-B1 COMPOUNDS FOR TREATMENT OF CANCER GTX INC (US) 2018-12-12 EP disclosed
US-20170226086-A1 COMPOUNDS FOR TREATMENT OF CANCER GTx. Inc. (US) 2017-08-10 US disclosed
US-9447049-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2016-09-20 US disclosed
EP-3064204-A1 COMPOUNDS FOR TREATMENT OF CANCER GTx, Inc. (US) 2016-09-07 EP disclosed
US-9334242-B2 Compounds for treatment of cancer GTX, INC. (US) 2016-05-10 US disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-20170226086-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885
US-11465987-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 RAB9A 1147/4885MEN1 165/4885KMT2A 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.